MedPath

Double Closure of Nasal Layer in Alveolar Cleft Grafting

Not Applicable
Completed
Conditions
Alveolar Cleft
Interventions
Procedure: platelet rich fibrin
Procedure: collagen membrane
Registration Number
NCT05988086
Lead Sponsor
Tanta University
Brief Summary

The aim of this prospective study is to evaluate both clinically and radiologically the efficacy of using autologous platelets rich fibrin versus collagen membrane for nasal layer closure in secondary alveolar cleft repair.

Detailed Description

Patients and methods: Twenty-four patients with alveolar clefts will be included in this study. The patients will be evaluated with age ranging between (7 - 12) years. The patients will be received, clinically and radiologically examined, and managed at the Oral and Maxillofacial surgery Department, Faculty of Dentistry, Tanta University.

The selected children should possess the following criteria: Their permanent canines either not or partially erupted, has no systemic disorder which can affect the grafting outcome and healing process such as juvenile diabetes mellitus, kidney, liver, or blood diseases and has no associated craniofacial syndromes. The patients will be classified into two groups according to incorporation of autologous platelet rich fibrin or collagen membrane for nasal layer closure with the grafting material, as follow: Group 1: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone. Group 2: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.

Preoperative evaluation of alveolar cleft site:

all patients will be examined clinically and radiologically. Clinical examination: This will consider the stability of maxillary segments, presence of old scar, asymmetry of the alar base, presence of oronasal fistula, and the presence of erupting teeth in the cleft.

Radiological examination: Panoramic radiographs will be done for each patient and examined as regard: the morphology of the cleft area, the size of the cleft side, the presence or absence of permanent lateral incisor and canine, the development of root length, and stage of eruption of permanent canine and lateral incisor. In addition, Axial computed tomography (CT) scans will be done for each patient to assess and measure local bone mineral density of grafted alveolar bone cleft.

Postoperative evaluation of the grafted site:

The grafted site will be evaluated clinically for healing condition at the follow up periods (1st week, then 1st , 3rd ,6th ,and 9th month postoperatively) ; regarding the presence of inflammation or infection , the soft tissue scar overlying the bone graft , tenderness of bone graft site , recurrence of oronasal fistula , alveolar ridge contour in cleft region and eruption of cleft related teeth . Radiological evaluation will be done for each patient using Axial computed tomography (CT) scans at the follow up period (3rd and 9th month postoperatively) to assess and measure local bone mineral density.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  1. patients with unilateral alveolar cleft
  2. the patient's permenant canines either not or partially erupted
  3. medically free patients
Exclusion Criteria
  1. patients with bilateral alveolar cleft
  2. medically compromised patients
  3. Any associated craniofacial syndromes.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1: platelet rich fibrinplatelet rich fibrinGroup 1: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
Group 2:collagen membranecollagen membraneGroup 2: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
Primary Outcome Measures
NameTimeMethod
inflammation score scale1 month

0 no inflammation, 1-3 mild inflammation,4-7 moderate inflammation,8-10 severe inflammation

density of bone1 month

density of bone to measure (D1,D2,D3,D4) Frome 150HU to 1250HU

visual analogue scale1 month

0 representing no pain and 10 representing the highest level of pain

Secondary Outcome Measures
NameTimeMethod
bone mineral density.9 months

density of bone to measure (D1,D2,D3,D4) Frome 150HU to 1250HU

Trial Locations

Locations (1)

Egypt

🇪🇬

Tanta, Egypt

© Copyright 2025. All Rights Reserved by MedPath